Improvements in breast cancer survival over time, related to adjuvant treatment and node status

European Journal of Surgical Oncology

Volumn 35, Issue 2, 2009, Pages 151-155

  Imkampe, A K ^a   Bates, T ^a  

^a WILLIAM HARVEY HOSPITAL   (United Kingdom)

Author keywords

Adjuvant treatment; Breast cancer survival; Lymph node status

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 58149481968     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.02.010     Document Type: Article

References (18)

1. Peto R., Boreham J., Clarke M., Davies C., and Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355 9217 (2000) 1822
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 9503 (2005) 2087-2106
4. Mariotto A., Feuer E.J., Harlan L.C., Wun L.M., Johnson K.A., and Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 94 (2002) 1626-1634
5. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., and Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332 14 (1995) 901-906
6. Hartman A.R., Fleming G.F., and Dillon J.J. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin Breast Cancer 2 2 (2001) 138-143
7. Castiglione-Gertsch M., Johnsen C., Goldhirsch A., et al. The international (Ludwig) breast cancer study group trials I-IV: 15 years follow-up. Ann Oncol 5 8 (1994) 717-724
8. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 14 (2006) 1658-1667
9. Boyages J., Taylor R., Chua B., et al. A risk index for early node-negative breast cancer. Br J Surg 93 5 (2006) 564-571
10. Arnesson L.G., Smeds S., and Fagerberg G. Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. Eur J Surg 160 5 (1994) 271-276
11. Wood W.C., Anderson M., Lyles R.H., et al. Ann Surg 235 6 (2002) 859-862
12. Fisher B., Dignam J., Tan-Chiu E., et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93 2 (2001) 112-120
13. Fisher B., Jeong J.H., Bryant J., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet 364 9437 (2004) 858-868
14. Rosen P.R., Groshen S., Saigo P.E., Kinne D.W., and Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7 3 (1989) 355-366
15. Quiet C.A., Ferguson D.J., Weichselbaum R.R., and Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 13 5 (1995) 1144-1151
16. Chia S.K., Speers C.H., Bryce C.J., Hayes M.M., and Olivotto I.A. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 9 (2004) 1630-1637
17. Joensuu H., Isola J., Lundin M., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9 3 (2003) 923-930
18. Rosen P.P., Groshen S., Kinne D.W., and Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11 11 (1993) 2090-2100